<DOC>
	<DOCNO>NCT02924233</DOCNO>
	<brief_summary>This phase 1b/2b study investigate safety preliminary antitumor effect Sym004 combination nivolumab versus nivolumab monotherapy administer every second week .</brief_summary>
	<brief_title>Sym004 Combination With Nivolumab Versus Nivolumab Monotherapy EGFR-amplified Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Main Signed date write informed consent Male female â‰¥18 year age time inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 3 month assess Screening Histologically cytologically confirm , locally advanced metastatic squamous NSCLC Main Any antineoplastic agent ( standard investigational ) within 2 week prior start trial treatment Radiosurgery radiotherapy target lesion within 2 week prior start trial treatment Prophylactic use hematopoietic growth factor within 1 week prior start trial treatment Active Central Nervous System ( CNS ) metastases carcinomatous meningitis Women pregnant Women breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Squamous</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>